Loading stock data…
PASG
$4.57-0.40 (-8.05%)
Pre-Market$4.58+0.01 (+0.23%)· Last close May 4
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Passage Bio, Inc. in the Healthcare sector is trading at $4.57. The stock is currently near its 52-week low of $4.52, remaining 46.9% below its 200-day moving average. Technical signals show oversold RSI of 13 and bearish MACD signal, explaining why PASG maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 13) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.57
Potential Upside
5%
Whystock Fair Value$4.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Hold
Mean target$11.40+149.5%
Range$7.00 – $23.00
Fundamentals
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficienc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-242.72%
Volume
Today's trading volume
83,389
Recent News
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a r
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
Passage Bio (PASG) is "undervalued" given PBFT02's distinct profile, with the US Food and Drug Admin
Intel upgraded, Reddit initiated: Wall Street's top analyst calls
Intel upgraded, Reddit initiated: Wall Street's top analyst calls
Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.